Reduction of tumor necrosis factor induced nuclear factor-κB nuclear translocation and DNA binding by dexamethasone in human osteoarthritic synovial tissue explants

Journal of Rheumatology

Volumn 29, Issue 4, 2002, Pages 787-795

  Lehmann, Thomas ^a   Murphy, Christian ^a   Zahra, David G ^a   Handel, Malcolm L ^a  

^a PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Glucocorticoid; Nuclear factor b; Synovium; Tumor necrosis factor

Indexed keywords

DEXAMETHASONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR;

ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA BINDING; ELECTROPHORETIC MOBILITY; EXPLANT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JOINT PROSTHESIS; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; QUANTITATIVE ASSAY; SYNOVIUM;

ANTI-INFLAMMATORY AGENTS; CELLS, CULTURED; DEXAMETHASONE; DNA; DNA-BINDING PROTEINS; DRUG COMBINATIONS; FIBROBLASTS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; NF-KAPPA B; OSTEOARTHRITIS; RECOMBINANT PROTEINS; SYNOVIAL MEMBRANE; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036222858     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Nuclear factor-κB - A pivotal transcription factor in chronic inflammatory diseases
2. Nuclear factor-κB in rheumatoid synovium: Localization of p50 and p65
3. Activation of the transcription factor nuclear factor-κB in human inflamed synovial tissue
4. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors
5. Activation of nuclear factor-κB-dependent transcription by tumor necrosis factor-α is mediated through phosphorylation of RelA/p65 on serine 529
6. The glucocorticoid receptor inhibits NF kappa B by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain
7. Glucocorticoids repress NF-κB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell
8. Defining therapeutic targets by using adenovirus: Blocking NF-κB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators
9. NF-κB activation provides the potential link between inflammation and hyperplasia in the arthritic joint
10. Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor κB decoy oligodeoxynucleotides as a gene therapy
11. Essential role of T cell NF-kappa B activation in collagen-induced arthritis
12. The effect of dexamethasone on the expression of activated NF-κB in adjuvant arthritis
13. Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids
14. Immunosuppression by glucocorticoids: Inhibition of NF-κB activity through induction of IκB synthesis
15. Physical association and functional antagonism between the p65 subunit of transcription factor NF-κB and the glucocorticoid receptor
16. Negative cross-talk beween RelA and the glucocorticoid receptor: A possible mechanism for the antiinflammatory action of glucocorticoids
17. Glucocorticoid-mediated repression of inflammatory cytokine production in fibroblast-like rheumatoid synoviocytes is independent of nuclear factor-kappa B activation induced by tumor necrosis factor alpha
18. Glucocorticoid-mediated repression of NF-κB activity in endothelial cells does not involve induction of IκBα synthesis
19. Platelet-derived growth factor and IL-1 interactions in rheumatoid arthritis. Regulation of synoviocyte proliferation, prostaglandin production, and collagenase transcription
20. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells
21. Concepts of pathogenesis and emerging treatments in rheumatic diseases: Transcription factors
22. Involvement of nuclear factor κB in the regulation of cyclooxygenase-2 expression by interleukin-1 in rheumatoid synoviocytes
23. Synovial fluid-induced nuclear factor-κB DNA binding in a monocytic cell line
24. Nuclear factorkappa B in T cells from patients with rheumatic diseases: A preliminary report
25. Involvement of simultaneous multiple transcription factor expression, including cAMP responsive element binding protein and OCT-1, for synovial cell outgrowth in patients with rheumatoid arthritis
26. NF-kappa B regulation by I kappa B kinase in primary fibroblast-like synoviocytes
27. 2 production by the antiinfiammatory cytokines interleukin-4, interleukin-10, and interleukin-13 in osteoarthritic synovial fibroblasts
28. NF-kappa B regulates VCAM-1 expression on fibroblast-like synoviocytes
29. High DNA-binding activity of transcription factor NF-κB in synovial membranes of patients with rheumatoid arthritis
30. Activation of transcription factor NF-κB in human synovial cells in response to tumor necrosis factor α
31. Quercetin, a bioflavonoid, inhibits the induction of interleukin 8 and monocyte chemoattractant protein-1 expression by tumor necrosis factor-alpha in cultured human synovial cells
32. Inhibition of IL-6 and 1L-8 induction from cultured rheumatoid synovial fibroblasts by treatment with aurothioglucose
33. Thiol-reactive metal compounds inhibit NF-kappa B activation by blocking I kappa B kinase
34. Glucocorticoids suppress tumor necrosis factor-α expression by human monocytic THP-I cells by suppressing transactivation through adjacent NF-κB and c-Jun-activating transcription factor-2 binding sites in the promoter
35. The effects of a T cell-specific NF-κB inhibitor on in vitro cytokine production and collagen-induced arthritis
36. Regulation of interleukin-1β-induced interleukin-6 gene expression in human fibroblast-like synoviocytes by glucocorticoids
37. FK506 augments glucocorticoid-mediated cyclooxygenase-2 downregulation in human rheumatoid synovial fibroblasts
38. Transcription factors Ap-1 and NF-κB: Where steroids meet the gold standard of anti-rheumatic drugs
39. Inhibition of transcription factors by antiinflammatory and antirheumatic drugs: Can variability in response be overcome
40. Inhibition of the DNA-binding activity of NF-kappa B by gold compounds in vitro
41. Inhibition of NF-κB by sodium salicylate and aspirin
42. Sulfasalazine a potent and specific inhibitor of nuclear factor kappa B
43. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-κB activation and gene expression
44. Inhibition of AP-1 binding and transcription by gold and selenium involving conserved cysteine residues in Jun and Fos
45. D-Penicillamine causes free radical-dependent inactivation of activator protein-1 DNA binding
46. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A